A Phase 1b Safety and Feasibility Study of Personalized Immunotherapy in Adults With Advanced Cancers
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2018 Planned End Date changed from 1 Jun 2022 to 1 Aug 2022.
- 10 Sep 2018 Planned primary completion date changed from 1 Jun 2021 to 1 Aug 2021.
- 10 Sep 2018 Status changed from not yet recruiting to recruiting.